
Supplementary Figure 1



Supplementary Figure 2

A. Forward- 5' ACGTTGGATGTCATTTCCTGTAGTGTGCTC Reverse- 5' ACGTTGGATGGCCGAAACCTGGACCAAAG Extension- 5' GAGGAGGTCGTCA CCGCCGGAAA

В.

chr1:153963178-153963314

chr1:153963239

GTCATTTCCTGTAGTGTGCTCtatataaggggcaggatttccgctttcgctcct	54
ttccggcggtgacgacctacgcacacgagaacatgcctgtgagtgCTTTGGTCC	108
Δαρπταραγία	118

C.

SCORE	STAF	RT END	QSIZE	IDENTITY	CHR.	STRAND	START	END	SPAN
118	1	118	118	100.0%	1	+	153963187	153963304	118
38	53	92	118	97.5%	12	-	3321078	3321117	40
37	52	92	118	95.2%	11	-	116906762	116906802	41
35	54	92	118	94.9%	1	-	202441240	202441278	39
32	52	92	118	84.3%	1	+	38021815	38021853	39

Validation of the specificity of the oligos used for the sequenom analysis, to the mutation region of *RPS27* gene. A. description of the sequence used for sequenome analysis. B. the sequence of the amplified genomic region as obtained from the *in silico* PCR analysis. The sequence of the primers is described as Caps letters. The genomic location of the mutation is pointed by an arrow. C. BLAT analysis of the amplified region of *RPS27* gene used as a template for the extension step. The table describe the location and % of identity of the different homologous regions in the genome to the *RPS27* gene. The *in silico* PCR and the BLAT analysis were performed using the UCSC website (http://genome.ucsc.edu/index.html).